COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Covid Alert


Print ISSN:-2394-6784

Online ISSN:-2394-6792

CODEN : IJPOF3

Current Issue

Year 2020

Volume: 7 , Issue: 2

  • Article highlights
  • Article tables
  • Article images

Article Access statistics

Viewed: 154

Emailed: 0

PDF Downloaded: 118


Nayak, Kumari, and Agrawal: Immunohistochemical expression of p53 in serous carcinoma of ovary and its correlation with clinicopathological parameters


Introduction

Ovarian cancer accounts for 2.5% of all malignancies among females and 5% of female cancer deaths because of low survival rates due to late diagnosis.1 Age, family history of ovarian or breast cancer and inheritance of BRCA-1, BRCA-2 gene mutations are significant risk factors associated with increased pre valence of ovarian tumours. Ovarian cancer comprises of group of malignancies differentiated by cell or site of their origin, pathologic grade, risk factors, prognosis, and treatment.3, 2 Epithelial tumours of ovary constitute two third of all the ovarian neoplasm and their malignant forms represent about 90% of all the ovarian cancers.4 Recent molecular and genetic studies suggest that epithelial ovarian cancer can be grouped into two broad categories: Type I and Type II. With clinical differences, there are also notable genetic differences. While, Type 1 cancers are associated with mutations in ARID1A, KRAS, PIK3CA, BRAF and PTEN ; the majority of Type 2 cancers are associated with mutations in p 53.5 Based on recent two-tier binary grading system Serous carcinoma of ovary is now classified into low grade and high grade carcinoma and further suggests that high grade and low grade carcinoma does not represent two different grades of the same tumour but represent two different tumour types instead.6 Based on molecular and genetic studies Low grade serous carcinoma is considered as Type I and High grade serous carcinoma considered as Type II tumour.

Most frequently mutated gene in ovarian carcinoma is p53 gene, a type of tumour suppressor gene.7 Studies have shown that p53 gene is mutated in about 50-80% of ovarian carcinoma.8

LGSOC lacks p53 gene mutations and is considered to arise from borderline tumours. In contrast HGSOC arises as denovo and it has been suggested that 100% of HGSOC are in fact p53 mutated.9, 5

Though, it is considered that Nucleotide sequencing is the most reliable technique to detect gene mutation, but due to time and effort involved, it is rarely used as a diagnostic tool. Therefore Immunohistochemical analysis of p53 expression is commonly used as a mimic for mutational analysis.12, 11, 10

The present study was conducted to evaluate immunohistochemical expression of p53 in serous carcinoma of ovary and its correlation with clinicopathological parameters.

Materials and Methods

The present study was a single-centre, prospective study. Total 18 histopathologically diagnosed cases of serous carcinoma were considered in the present study. Based on recent two-tier binary grading system, Serous ovarian carcinoma was histologically classified into low grade and high grade. All the relevant clinical history, investigation findings and serum CA-125 value were collected from patient case file. Staging was performed according to FIGO criteria. Immunohistochemical staining was done for p53 with Dako Flex monoclonal mouse anti-human p53 protein clone DO-7 over FFPE tissue sections which were mounted on poly-L-Lysine coated slides. Further sections were deparaffinised and microwave method was used for antigen retrieval. After that endogenous peroxidas e blocking was performed. Then, incubation with monoclonal primary antibody was done for 30 minutes in humidifying chamber. Then, secondary antibody conjugated with horseradish peroxidase enzyme was applied for 30 minutes. Thereafter, freshly prepared di-amino benzidine (DAB) was applied for 10 minutes. Finally haematoxylin was used for counterstaining and slides were then dehydrated and mounted.

Nuclear staining was acknowledged as a positive reaction. Scoring for p53 was based on proportion of cells in a given tumour specimen showing distinct nuclear positivity. p53 scoring result were done as follows:14, 13 0 (negative or occasional positive), 1+(<10% cells positive), 2+ (10-25% cells positive),3+ (26-50 % cells positive), 4+ (51-75% cells positive), 5+(> 75% cells positive).All the statistical analysis were done using IBM SPSS statistical software version 23.

Results

Out of total 18 cases of serous carcinoma, 14 cases were high grade serous carcinoma and 4 cases were low grade serous carcinoma (Table 1). All the cases were in the age group of 40 to 60 years of age group.

In the present study (Table 2), it was observed that, out of 14 HGSOC cases, 11 cases (78.57%) were diagnosed in advanced stages (FIGO Stage III and IV) while 3 out of 4 (75%) cases of LGSOC were diagnosed in comparatively earlier stages (FIGO stage I and II).

Number of p53 positive cases in LGSOC was 2/4 (50%) and in HGSOC it was 14/14(100%), showing a statistically significant difference (p<0.05) (Table 3). Correlation analysis shows a strong positive correlation of p53 expression with grade of serous carcinoma (Spearmanʼs rho correlation ρ=0.701, p =0.001). Higher level (3+,4+, and 5+) and diffuse and patchy expression of p53 was expressed in HGSOC (Figure 5). The expression of p53 in LGSOC was focal reflected in low expression score(1+ and 2+)(Figure 2).

Mean value of CA -125 was significantly higher in HGSOC (2059±1460.55) than LGSOC (553.37±278.52) with the difference being statistically significant (p<0.01). On correlation analysis, preoperative CA-125 levels had strong positive correlation with grade of serous carcinoma. (Spearmanʼs rho correlation ρ=0.695, p=0.000).

Table 1

Distribution of Serous carcinoma according to two-tier binary grading system

Grade Number Percentage (%)
Low 4 22.22
High 14 77.78
Total 18 100

Table 2

Distribution of Low grade serous carcinoma and High grade serous carcinoma according to FIGO staging system

FIGO Stage
Stage 1 Stage II Stage III Stage IV
Low grade serous carcinoma 1 2 1 --
High grade serous carcinoma 0 3 7 4

Table 3

Pattern of p53 expression in low and high grade serous carcinoma of ovary

S.No. Histotype Total No Positive cases Negative cases p-value
Number Percentage (%) Number Percentage (%)
1 Low grade serous carcinoma 4 2 50 2 50 <0.05
2 High grade serous carcinoma 14 14 100 0 0

Table 4

Comparative analysis of p53 expression in low and high grade serous carcinoma of ovary with other studies

Low grade High grade P value
Giurgea et al 1/8 9/16 p=0.06
Naik et al 1/2 7/7 p<0.05
O´Neil et al 30/47 4/22 p<0.05
Marinas et al 5/8 12/12 p=0.000
Sallum et al 4/22 59/85 p<0.0001
Present study 2/4 14/14 <0.00001

Table 5

Comparative analysis of preoperative serum CA-125 (median value in U/mL) in low and high grade serous carcinoma of ovary with other studies

Grade Fader et al Sallum et al Present study
Low grade 119.1 98 588.25
High grade 246.7 954 1583
p value p <0.001 p<0.001 p<0.01

Figure 1

LGSOC: Branching papillary structure with psammoma bodies (H&EX100)

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/766b487a-8b1a-4c1c-9fcc-57ee4751a6c1/image/3ebfe4e8-3413-4ec1-b1b3-3da044a18d7f-uimage.png

Figure 2

LGSOC: Positive p53 expression (score 2+) (IHCX100)

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/766b487a-8b1a-4c1c-9fcc-57ee4751a6c1/image/7a479c9a-add0-46c6-872e-72e0de8ec747-uimage.png

Figure 3

HGSOC: Papillary and solid pattern (H&E X100)

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/766b487a-8b1a-4c1c-9fcc-57ee4751a6c1/image/734b812b-6505-4999-83d4-7ad03e691574-uimage.png

Figure 4

HGSOC: Pleomorphic tumour cells, high mitotic index and abnormal mitotic figure(H&E X400)

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/766b487a-8b1a-4c1c-9fcc-57ee4751a6c1/image/a56aba24-5233-44d5-878c-b5e9bfbf59c2-uimage.png

Figure 5

HGSOC: Positive p53 expression (score 5+) (IHC X100)

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/766b487a-8b1a-4c1c-9fcc-57ee4751a6c1/image/c75a588c-e916-4304-8f72-a7b152a02099-uimage.png

Graph 1

Distribution of serous carcinoma according to two- tier binary grading system)

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/766b487a-8b1a-4c1c-9fcc-57ee4751a6c1/image/1d64773e-cf6e-45fc-8c5a-a9839e0c1431-uimage.png

Figure 6

Expression of p53 in low grade serous carcinoma and high grade serous carcinoma of ovary

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/766b487a-8b1a-4c1c-9fcc-57ee4751a6c1/image/be2300e1-14b1-424a-beba-849113317a43-uimage.png

Discussion

Low grade and high grade serous carcinoma harbour different molecular abnormalities and have different clinical courses. LGSOC are slow growing tumours and have mild to moderate nuclear atypia with occasional mitotic figure. Micropapillary architecture is typical, necrosis is unusual and psammoma bodies are much more frequent (Figure 1). They arise from adenofibroma, atypical proliferative serous tumour or serous borderline tumours and associated with frequent mutations of the KRAS, BRAF or ERBB2 genes. They rarely harbour p 53 mutations and are genetically stable.15, 4, 2 In contrast, HGSOC is rapidly growing, highly aggressive and diagnosed mostly at advanced stages. They are typically composed of solid masses of cells with slit like spaces. Papillary areas are common. Nuclei are large, hyperchromatic and Pleomorphic. Multinucleation is common and mitosis is frequent (Figure 4, Figure 3). Recent studies suggest that a significant number of HGSOC cases originate from the intraepithelial carcinoma in the fallopian tube.17, 16, 15, 4, 2

HGSOC cases are associated with higher CA-125 values and have worse prognosis when compared with LGSOC.18 The two types of serous ovarian carcinoma harbour different molecular abnormalities and have different clinical courses. These data from the literature were confirmed in our study.

Sallum et al18 in their study observed that women with HGSOC accounted for a significantly higher proportion of advanced stage disease (80% vs 42.9%,p<0.001) compared with women having LGSOC. Similar findings were observed in the present study with cases in advanced stages accounting for HGSOC being much higher than LGSOC (78.57% vs 25%, p<0.001).

Similar to other studies reported in literature (Table 4) we too observed that HGSOC was associated with higher and diffuse p53 expression. In the study conducted by Sallum et al (2018)18 (p<0.0001), Naik et al (2015)19(p<0.05), O´Neil et al(2005)13 (p<0.05) and Marinas et al(2012)20 (p=0.000), there was statistically significant difference between p53 expression and grade of serous carcinoma, well correlated with our study(p<0.00001). Whereas Giurgea et al (2012)21 (p= 0.06) found no significant correlation between p53 immunostaining and grade of serous carcinoma. Sallum et al (2018)18 in their study observed that, p53 expression was diffuse in 68.2% of cases, completely absent in 30.6% and was focal in 1.2% of HGSOC, compared with LGSOC, which showed diffuse expression in 9.5%, complete absence in 81.0% and focal expression in 9.5% (p < 0.0001). In the present study, we too observed that higher staining of p53 (4+ and 5+) was present in HGSOC. In contrast, in LGSOC 0 to 2+ staining pattern was observed. 100% cases of HGSOC in contrast to 50% cases of LGSOC showed positive immunostaining for p53 and the difference was statistically significant(p<0.00001).

In the present study we observed that median value of preoperative CA-125 in the low grade serous carcinoma (588.25U/mL) was significantly lower than those with high-grade serous carcinoma (1583U/mL; p < 0.01), similar to other studies (Table 5) conducted by Fader et al (2013)22 (p<0.001) and Sallum et al (2018)18 (p<0.001). Sylvia et al (2012)23 and Cooper et al (2002)24(p<0.001) in their study also observed that, median CA-125 levels were significantly increased in high grade tumours.

Limitation of our study

Sample size was small.

Conclusion

The significant difference of p53 expression between l ow grade and high grade serous carcinoma of ovary strongly suggests that the underlying pathogenesis of these two tumours is different. Higher p53 expression mainly in high grade carcinoma suggests its prominent role in the pathogenesis of high grade serous carcinoma of ovary. Further association of high grade serous ovarian carcinoma with advanced FIGO stages and higher CA-125 value suggests aggressive nature of this tumour.

Source of funding

None.

Conflict of interest

None.

References

1 

R L Siegel K D Miller A Jemal Cancer statisticsCA Cancer J Clin201868730

2 

R J Kurman Shih IeM The dualistic model of ovarian carcinogenesis: revisited, revised, and expandedAm J Pathol2016186733747

3 

N Wentzensen E M Poole B Trabert Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort ConsortiumJ Clin Oncol20163428882898

4 

M Kobel S E Kalloger P M Baker C A Ewanowich J Arseneau V Zherebitskiy Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian studyAmJ Surg Pathol201067984993

5 

R J Kurman I M Shih Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigmHum Pathol201142918931

6 

A Malpica M T Deavers K Lu D C Bodurka E N Atkinson D M Gershenson Grading ovarian serous carcinoma using a two-tier systemAm J Surg Pathol2004284496504

7 

B Khandakar S R Mathur L Kumar S Kumar S Datta Gupta V K Lyer Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapyBiomed Res Int2014

8 

J J Herod A G Eliopoulos J Warwick Niedobitek G Young L S Kerr D J . The prognostic significance of Bcl-2 and p53 expression in ovarian carcinomaCancer Res [Internet]199656921782184

9 

R Vang Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian StudyInt J Gynecol Pathol2016354855

10 

A Yemelyanova R Vang M Kshirsagar Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysisMod Pathol20112412481253

11 

B Murnyák T Hortobágyi Immunohistochemical correlates of TP53 somatic mutations in cancerOncotarget20167406491064920

12 

A J Cole T Dwight A J Gill Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencingSci Rep2016626191

13 

C J O’neill M T Deavers A Malpica An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasmsAm J Surg Pathol20052910341041

14 

R K Tiwari K Saha D Mukhopadhyay C Datta U Chatterjee T K Ghosh Evaluation of Preoperative Serum Levels of CA 125 and Expression of p53 in Ovarian Neoplasms: A Prospective Clinicopathological Study in a Tertiary Care HospitalJ Obstet Gynaecol India2014662107114

15 

R J Kurman M L Carcangiu C S Herrington WHO Classification of Tumours of Female Reproductive Organs. In WHO Classification of Tumours. 4. Aufl. Lyon: WHO Press2014WHO Press

16 

M Köbel A Reuss A Bois S Kommoss F Kommoss D Gao The biological and clinical value of p53 expression in pelvic high-grade serous carcinomasJ Pathol2010222191198

17 

N N Nik R Vang I M Shih R J Kurman Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinomaAnnu Rev Pathol201492745

18 

L F Sallum L Andrade S Ramalho WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosisOncotarget20189221581815827

19 

P S Naik S Deshmukh S G Khandeparkar Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical studyJ Midlife Health201564178183

20 

M C Marinaş D G Mogoş Cristiana Eugenia Simionescu A Stepan Florentina Tănase The study of p53 and p16 immunoexpression in serous borderline and malignant ovarian tumorsRom J Morphol Embryol201253410211102

21 

L N Giurgea C Ungureanu M S Mihailovici The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factorsRom J Morphol Embryol201253967973

22 

A N Fader J Java T C Krivak The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group studyGynecol Oncol20131323560565

23 

S Kumar P Dasari M Sylvia The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variablesIndian J Pathol Microbiol201255133

24 

B C Cooper A K Sood C S Davis J M Ritchie J I Sorosky B Anderson Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancerObstet Gynecol200210015964



jats-html.xsl

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license (creativecommons.org)